Ⅰ 武汉三鹰生物技术有限公司的地位
武汉三鹰生物技复术有限公司制成立之初,即瞄准了蛋白质组研究这一巨大的市场,并提出了抗体组的概念。抗体是识别研究蛋白质必不可少的工具,三鹰生物的目标是实施人类抗体组计划,即研究和制备人类蛋白组中所有蛋白质的抗体,探索大规模制备抗体的新技术,并完善抗原-抗体相互作用的高通量化、自动化及智能化的检测技术。目前已经是国内最大的抗体公司,也是全球抗体公司中最大规模的公司之一。公司产品90%以上销往欧美地区,在同行业中占首位。
Ⅱ 武汉三鹰生物技术有限公司的英文介绍
The mission of Proteintech Group, Inc is to develop, manufacture a wide spectrum of antibodies against all human proteins known as Human Antibody Projects, thus providing the most effective tools for the identification and quantization of the vast number of known or unknown disease markers. Our philosophy is to be a part of the solution of the research community by providing scientists with every possible antibody they will need and at a reasonable cost. As all founders of the company are bench-side researchers, we have the deepest appreciation for the highest standard of perfection that all scientists hold for their projects, and therefore we hold our procts to the same standard. As a part of this research community, we firmly committed to be a silent partner of every research laboratory and every research project.
Therefore it is the responsibility of Proteintech Group to offer researches with a variety of antibodies and related procts at highest quality as possible so that the researchers can focus on their creativity, skill and effort as well as funding, without ever having to concern with the quality of reagents used. We also committed to provide them at lowest possible cost because we understand that every dollar of the research grant is the result of hard work of the researchers. Every dollar we saved is a dollar they have earned.
As the silent partner in your research career, you can count on us to solve your supply and technical needs on antibodies and antibody related procts. We deeply understand that only if you succeed, we will succeed.
Proteintech Group offers a variety of polyclonal and monoclonal antibodies for your research. Each antibody is thoroughly tested for its ability to perform immunoprecipitation, immunoblotting and immunohistochemistry so that you can be confident in using them. Understanding each antibody has its unique applications and features, we also provide our customers with complete technical support and detailed instructions for each application. To maximize your research flexibility, we promise following services.
The antibody and antibody-related procts for research, biotech and clinical diagnostics constitute huge but unsaturated market in the world, and it is subject to a high growth trend. In the US, the National Institute of Health alone receives 17 billion dollars federal funding, among that, 1.7 billion, i.e. 10% is spent on antibody and related reagents. Many private pharmaceutical companies spent many fold more on antibodies and its related procts. Another growing market is the proteomic project (project to identify, profile all human proteins and their function), especially in the post genomic project period. Antibodies are the only type of reagents today to solve most problems in the Human Proteomic Project. It is estimated that some 300,000 different anti-human protein antibodies will be needed while there are only 10,000 Antigen specificities are available.
The mission of the Proteintech Group is to design, develop, and market antibody and antibody-chips in the Bioresearch field. The antibody will fill current market that accounts for a minimum of $ 1.7 billion dollars in potential sales. Each proct shall be priced to appeal to researchers that stresses lowest cost and convenient.
The procere of proction and marketing has been tested. Projections from studies have shown that with a 2 million dollar initial investment, the company would expect $24 million in sales in year three with a net profit of approximately $20 million. The company would expect to have $38 million in revenue by year five. The company would be self sustained in year one and will be able to break even between year one and two, purely based on antibody proction and sales.
In next five years, the estimated market of procts yielded from proteomic project would reach to 40 billion. The Proteintech Group is currently developing antibody chips (a collection of thousand antibodies arranged in arrays for quick identification and quantitation of known or unknown proteins in a mixture, such as in blood), a key proct of this market. With its advantages of it.
Ⅲ 关于western的请大侠赐教。我做的都绝望了。
抗体不行 这啥公司的都没听说过 至少也得买CST的吧 内参有么
Ⅳ 大家对美国Proteintech Group公司有什么认识吗
Proteintech 奖学金的成立
2009年底,美国Proteintech Group公司宣布在北京大学生命科学学院设立奖学金。双方签署了捐赠协议,并在北京大学教育基金会设立了专用账户。生命科学学院已利用社会资源先后设立了吕义长奖学金、郁采蘩奖学金等多项学院奖学金,用于奖励品学兼优的研究生。
Proteintech奖学金成立目的
为激励青年科学工作者不断奋进,带动中国生命科学领域科研和产业的快速腾飞,在Proteintech Group公司总裁李建勋博士的支持下,公司决定在北京大学生命科学学院设立Proteintech奖学金,用于奖励在科研工作中做出突出贡献的生命科学学院硕士和博士研究生。Proteintech奖学金于2010年正式启动,每年评审一次。奖学金获得者还将有机会参与公司的生产实习、科技创新和社会实践等活动。
Proteintech Group公司总裁李建勋博士简介
Proteintech Group公司创始人、总裁李建勋博士,是一位杰出的分子生物学家和企业家。
作为学者,李建勋在他的研究领域取得了骄人的成就。他1985年考入美国纽约市立大学攻读博士,毕业后到美国洛克菲勒大学做了4年博士后,1997年被美国伊利诺斯州州立大学聘为副教授,3年后获终身教授资格。从1996年至今他一直担任美国烟草协会研究基金的首席科学家,同时承担美国国立卫生院的重大科研课题,2001年被美国心脏协会授予资深科学研究基金,前后承担了约240万美元的各种科研项目,从2003年开始也成为国内973计划的共同申请人。
作为企业家,李建勋认准了抗体市场的巨大潜力,在美国创办了Proteintech Group, inc.并出任董事长。Proteintech Group, inc.于2001年在美国芝加哥成立,是一家由留美科学家创办的生产、销售抗体及重组蛋白的生物技术公司。2001年在中国成立全资子公司武汉三鹰生物技术有限公司,2006年在英国曼彻斯特成立欧洲分公司。Proteintech Group致力于开发针对所有人类蛋白的抗体——人类抗体组计划,迄今已生产出针对10,000种不同人类蛋白的10,000种抗体。公司产品被各大学术期刊发表的论文频繁引用,在国际学术界建立了独具特色的品牌和牢固的地位,公司产品以出口为主,目前已在美、日、欧洲各国的生物医学领域拥有稳定的顾客群,在当今方兴未艾的人类蛋白质组计划已占据了一席之地。
Ⅳ 除了sigma公司,哪里还可以买到抗原蛋白。制备多克隆抗体时,选用的抗原纯度要达到多少
其他很多公司Fantibody abcam 武汉三鹰等等 纯度要根据你不同实验来确定
Ⅵ 武汉三鹰生物技术有限公司怎么样明天要去面试,网上查得到的,我都看了,要更详细具体的信息
很好.大专毕业
Ⅶ 国内哪家抗体公司好
我是代理商,一般我们顾客选择的比较多的是epitomics的抗体,价格比较便宜而且质量很不错,能选择的余地也比较大。如果想了解详细些可以跟我联系
Ⅷ 武汉三鹰生物技术有限公司的概况
公司主要生产人类蛋白组抗体及相关产品。目前已有多克隆抗体10000多种,单克隆抗体300余种,融合蛋白13000多种,即已经完成了人类基因组三分之一以上的基因的表达,成为全球最大的重组蛋白生产公司。此外,公司还有人类全长cDNA 22000条,并拥有自己的实验动物基地。公司产品以出口为主,目前已在美、日、欧洲各国的生物医学领域拥有稳定的顾客群。
Ⅸ 武汉三鹰生物技术有限公司怎么样
简介:武汉三鹰生物技术有限公司(,Inc)是一家由留学人员和专业管理人员组成的新型生物技术外资企业,成立于2000年11月,2002年5月被认定为高新技术企业,是全国抗体生产公司的领头羊。公司总部和实验室设在武汉东湖新技术开发区关东科技园内,在美国和英国拥有自己的销售网络和网站(wwww.ptglab.com)。公司主要生产人类蛋白组抗体及相关产品。目前已有多克隆抗体10000多种,单克隆抗体300余种,融合蛋白13000多种,即已经完成了人类基因组三分之一以上的基因的表达,成为全球最大的重组蛋白生产公司。此外,公司还有人类全长cDNA22000条,并拥有自己的实验动物基地。公司产品以出口为主,目前已在美、日、欧洲各国的生物医学领域拥有稳定的顾客群。
法定代表人:JIANXUNLI
成立时间:2003-01-27
注册资本:100万人民币
工商注册号:420100400007932
企业类型:有限责任公司(外国法人独资)
公司地址:武汉市东湖新技术开发区高新大道666号光谷生物城生物创新园D3-3栋